Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - AOL
And it's not too late to get in on the action.
www.aol.com
Instead of cutting into tirzepatide's sales, the company seems to be signaling to investors that retatrutide will target patients who are more obese and metabolically challenged, setting the product apart in the market. That ought to make for some interesting talks in doctors' offices.
Patient: Hey doc, I hear there's this amazing new drug out there and that I'll drop a lot of weight
Doc: Yeah, but you're not fat enough
Patient: Should I put on some weight
Doc: No, just take the less effective medication
Nine months later.....
Patient: Hey doc, I didn't lose enough, can I try that new drug?
Doc: Oh no, we have an adjunct called eloralintide that would be much better to add to the tirzepatide. Now you have to pay for two scripts.